

**Assessment tools for certification
in the discipline "Faculty therapy"
for students of the educational program
specialist degree in the specialty/direction of training
31.05.01 Medical business,
direction (profile) Medical business,
form of study full-time
for the 2023-2024 academic year**

1. Evaluation tools for conducting current certification in the discipline

Current certification includes the following types of tasks: testing, solving situational problems, evaluating the development of practical skills, and interviewing control questions.

1.1. Examples of test tasks

Verifiable indicators of competence achievement: UC-1.1.3; GPC-1.1.1; GPC-4.1.1, GPC-4.1.2, GPC-4.1.3; GPC-5.1.1; GPC-6.1.1, GPC-6.1.2; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3; GPC-10.1.1, GPC-10.1.2; PC-1.1.1 PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8; PC-2.1.4; PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4.

1. The most important risk factor for COPD is:

- a) exposure to household and industrial pollutants
- b) overweight
- c) smoking
- d) allergies
- e) frequent colds

2. The drugs of choice for basic treatment of bronchial asthma are:

- a) systemic glucocorticosteroids
- b) methylxanthines
- c) inhaled glucocorticosteroids
- d) secretolytics
- e) extended-acting b₂ agonists

3. Chronic obstructive pulmonary disease is characterized by all of the following, except:

- a) smokers are more likely to get sick
- b) the disease begins after the age of 40 years
- c) gradual progression
- d) improvement in winter time
- e) more than half of COPD patients are allergic

4. Bronchial asthma is characterized by all of the following, except:

- a) transient bronchial obstruction
- b) the disease often begins in childhood
- c) smokers are more likely to get sick
- d) improvement in spring and summer
- e) more than half of patients with bronchial asthma suffer from allergies

5. Differential diagnosis of chronic obstructive pulmonary disease should be carried out with all of the above, except for:

- a) bronchial asthma

- b) pulmonary tuberculosis
- c) pulmonary hemorrhage
- d) left ventricular heart failure
- e) bronchiectasis

6. Which of the following symptoms is not typical for a choking attack in bronchial asthma:

- a) sudden onset
- b) expiratory dyspnea
- c) participation of auxiliary muscles in the act of breathing
- d) hemoptysis
- e) scattered dry wheezing in the lungs

7. The study of the function of external respiration in bronchial asthma reveals:

- a) increasing decrease in FEV1 and Tiffno index in accordance with the stage of the disease
- b) an increase in FEV1 of more than 15% after the b2-agonist test
- c) an increase in FEV1 of less than 15% after the b2-agonist test
- d) daily fluctuations in the peak expiratory rate of less than 15%
- e) the function of external respiration is not changed

8. The main radiological sign of pneumonia is:

- a) strengthening of the pulmonary pattern
- b) infiltration of lung tissue
- c) expansion of the lung root
- d) the presence of a cavity in the lung
- e) the presence of fluid in the pleural cavity

9. Nosocomial (nosocomial) pneumonia is considered to develop after hospitalization in a hospital through:

- a) 24 hours
- b) more than 14 days;
- c) 48 hours
- d) 72 hours
- e) 7 days

10. Complications of community-acquired pneumonia do not include:

- a) pleural effusion
- b) pneumothorax
- c) destruction and abscessing of lung tissue
- d) acute respiratory distress syndrome
- e) secondary bacteremia, sepsis

1.2. Example of a situational problem

Verifiable indicators of competence achievement: CC-1.2.1; GPC-1.2.1, GPC-1.2.2; GPC-4.2.1, GPC-4.2.2, GPC-4.2.3, GPC-4.2.4, GPC-4.3.1, GPC-4.3.2, GPC-4.3.3; GPC-5.2.1; GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.2.1, GPC-10.2.2; PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.

Patient G., 20 years old, was admitted to the clinic with complaints of general weakness, constant dull pain in the heart, pain in the knee and ankle joints and their swelling.

From the anamnesis: 2 weeks before hospitalization, he suffered a sore throat.

On examination: moderate condition. The body temperature is 38° C, There is swelling and hyperemia of the knee and ankle joints. In the lungs, breathing is vesicular, there is no wheezing. BH 20 in min. Heart rate is 100 beats per minute. Heart sounds are muffled, systolic murmur at the apex. Blood pressure=100/60 mm Hg. No peripheral edema.

In the blood test: leukocytes $10 \times 10^9/l$, ESR 34 mm / h; increased all indicators of inflammatory activity (fibrinogen 6,8 g/l, seromuroid 0,465 g/l, CRP 28 mg/l, ASL-O 625 units).

On the ECG: sinus tachycardia, reduced voltage of the teeth.

On ECHOCARDIOGRAPHY: uneven thickening of the anterior leaflet of the mitral valve, limited mobility of the posterior leaflet. Increased amplitude of ventricular septal pulsation.

Questions:

- 1) Your intended diagnosis.
- 2) What diseases should be differentiated between?
- 3) Your treatment strategy.

1.3. Examples of practical skills assessment tasks

Verifiable indicators of competence achievement: UC-1.2.1; GPC-1.2.1, GPC-1.2.2; GPC-4.2.1, GPC-4.2.2, GPC-4.2.3, GPC-4.2.4, GPC-4.3.1, GPC-4.3.2, GPC-4.3.3; GPC-5.2.1; GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.2.1, GPC-10.2.2; PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.

Interpretation of instrumental and laboratory research methods.

- 1) Chest X-ray: right-sided lower lobe pneumonia.
- 2) ECG interpretation: ventricular extrasystole.
- 3) Interpretation of a general blood test: iron deficiency anemia.

1.4. Examples of control questions for the interview

Verifiable indicators of competence achievement: UC-1.1.3; GPC-1.1.1; GPC-4.1.1, GPC-4.1.2, GPC-4.1.3; GPC-5.1.1; GPC-6.1.1, GPC-6.1.2; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3; GPC-10.1.1, GPC-10.1.2; PC-1.1.1 PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8; PC-2.1.4; PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4.

- 1) Dyslipidemia, their role in the development of atherosclerosis.
- 2) Epidemiology and risk factors for atherosclerosis and CHD.
- 3) Pathogenesis and pathomorphology of atherosclerotic lesions of the vascular wall.
- 4) The concept of coronary heart disease.
- 5) Classification of CHD.

1.5. Examples of test tasks

Verifiable indicators of competence achievement: UC-1.1.3; GPC-1.1.1; GPC-4.1.1, GPC-4.1.2, GPC-4.1.3; GPC-5.1.1; GPC-6.1.1, GPC-6.1.2; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3; GPC-10.1.1, GPC-10.1.2; PC-1.1.1 PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-

1.1.7, PC-1.1.8; PC-2.1.4; PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4.

1. The urease test is used for:

- a) determination of the acidity of gastric juice
- b) detection of *H. pylori*
- c) evaluation of the effectiveness of treatment of PJ
- d) studies of the enzyme-forming function of the stomach
- e) studies of the physical properties of gastric juice.

2. The group of M-cholinolytics includes:

- a) omeprazole
- b) atropine
- c) ranitidine
- d) kwamatel
- e) no-shpa

3. Extraesophageal manifestations of GERD include:

- a) reflux-induced bronchial asthma
- b) esophagocardial reflex (arrhythmias, chest pains after eating)
- c) changes in ENT barriers
- d) dental changes (caries, periodontal disease, aphthous stomatitis)
- e) all of the above

4. For the diagnosis of GERD, the following is crucial:

- a) clinic
- b) study of gastric secretion
- c) detection of *H. pylori*
- d) EGDS
- e) gastric X-ray examination

5. The cause of superhepatic jaundice is not:

- a) hemolytic anemia
- b) leukemia
- c) chronic hepatitis
- d) infections
- e) transfusion of incompatible blood

6. An increase in the activity of enzymes (ALT,AsAT,LDH,aldolase) is of the greatest practical importance for the diagnosis of:

- a) cytolytic syndrome
- b) hepatic cell failure syndrome
- c) cholestasis syndrome
- d) mesenchymal-inflammatory syndrome
- e) all of the above

7. A complication of cirrhosis of the liver is not:

- a) hepatic coma
- b) cirrhosis-cancer
- c) bleeding from dilated esophageal veins
- d) hemochromatosis
- e) V. portae thrombosis

8. A necessary condition for the diet of patients with hepatic encephalopathy is the restriction of:

- a) carbohydrates
- b) fats
- c) protein
- d) table salt
- e) liquids

9. The group of hepatoprotectors does not include:

- a) heptral
- b) phosphogliv
- c) essentielle
- d) thioctacid
- e) karsil

10. Hyperbilirubinemia with a predominance of the indirect bilirubin fraction is characteristic of:

- a) hemolytic jaundice
- b) parenchymal jaundice
- c) mechanical jaundice
- d) mesenchymal-inflammatory syndrome
- e) cytolytic syndrome

2. Evaluation tools for conducting intermediate certification in the discipline

Intermediate certification is conducted in the form of an exam.

Intermediate certification includes the following types of tasks: interview, solving a situational problem, interpreting an X-ray, ECG, and laboratory tests.

2.1. List of interview questions

#	Questions for intermediate certification	Verifiable indicators of achievement of competencies
Pulmonology		
1.	of Pneumonia. Modern understanding of the etiology and pathogenesis. Assessment of the severity of pneumonia. Criteria for diagnosis. Classification. Differential diagnosis.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-4.1.1, GPC-4.1.2, GPC-4.1.3, GPC-4.2.1, GPC-4.2.2, GPC-4.2.3, GPC-4.2.4, GPC-4.3.1, GPC-4.3.2, GPC-4.3.3; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3

2.	Features of the course of pneumonia depending on the pathogen. Pharmacotherapy with the position of evidence-based medicine. Effectiveness of therapy.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
3.	Community-acquired pneumonia. Etiology. Pathogenesis. Clinic. Diagnostic criteria. Indications for hospitalization. Treatment.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; About GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-1.1.1, PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8, PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
4.	Nosocomial pneumonia. Etiology. Pathogenesis. Risk groups. Clinic. Features of drug therapy. Ethical and deontological aspects of management of patients with nosocomial pneumonia.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
5.	Bronchiectasis. Etiology. Pathogenesis. Classification. Clinic. Diagnostic criteria. Complications.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-4.1.1, GPC-4.1.2, GPC-4.1.3, GPC-4.2.1, GPC-4.2.2, GPC-4.2.3, GPC-4.2.4, GPC-4.3.1, GPC-4.3.2, GPC-4.3.3; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3
6.	Bronchiectatic disease. Treatment. Complex therapy. Indications for surgical treatment. Prevention.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-

		7.2.3, GPC-7.3.1; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
7.	COPD. Modern aspects of etiology and pathogenesis. The role of industrial facilities in the Volgograd region in the development of COPD. Classification of COPD severity. Clinic. Characteristics of COPD types. Diagnosis and treatment based on international recommendations (GOLD). Differential diagnosis. Treatment.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; About GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-1.1.1, PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8, PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
8.	Bronchial asthma. Etiology. The role of industrial facilities and climatic conditions of the Volgograd region in the development of bronchial asthma. Pathogenesis. Classification. Diagnostic criteria. Assessment of the severity of the disease. Differential diagnosis.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-4.1.1, GPC-4.1.2, GPC-4.1.3, GPC-4.2.1, GPC-4.2.2, GPC-4.2.3, GPC-4.2.4, GPC-4.3.1, GPC-4.3.2, GPC-4.3.3; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3
9.	Clinical symptoms of bronchial asthma. Diagnostic criteria are clinical and allergic. Allergological tests (skin tests, provocative tests, determination of common and allergospecific IgE (household, food, pollen). Opportunities for immunological diagnostics in the Volgograd region.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-4.1.1, GPC-4.1.2, GPC-4.1.3, GPC-4.2.1, GPC-4.2.2, GPC-4.2.3, GPC-4.2.4, GPC-4.3.1, GPC-4.3.2, GPC-4.3.3; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3
10.	Standards for the treatment of bronchial asthma based on international recommendations (GINA).	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-3.1.1, PC-

		3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
11.	Complications of bronchial asthma. Asthmatic status, criteria for its diagnosis and stage of course. Chronic pulmonary heart disease. Rules for referring patients to the ITU.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; About GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-1.1.1, PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8, PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
Cardiology		
12.	Acute rheumatic fever. Etiology. Pathogenesis. Classification.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-4.1.1, GPC-4.1.2, GPC-4.1.3, GPC-4.2.1, GPC-4.2.2, GPC-4.2.3, GPC-4.2.4, GPC-4.3.1, GPC-4.3.2, GPC-4.3.3; GPC-5.1.1, GPC-5.2.1.
13.	Clinic of the main manifestations of acute rheumatic fever. Clinical and laboratory criteria. Flow options. Differential diagnosis. Diagnostic methods used in patients with rheumatic fever in the Volgograd region.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-4.1.1, GPC-4.1.2, GPC-4.1.3, GPC-4.2.1, GPC-4.2.2, GPC-4.2.3, GPC-4.2.4, GPC-4.3.1, GPC-4.3.2, GPC-4.3.3; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3
14.	Treatment of acute rheumatic fever. Prevention. Medical examination. Anti-relapse treatment.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
15.	Infectious endocarditis. Etiopathogenesis. Contributing factors. Classification. Clinic. Treatment. High-tech care in specialized hospitals of the Volgograd region. Ethical and deontological aspects of management of patients with infectious endocarditis. Medical	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; About GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-1.1.1, PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8, PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4; PC-

	examination.	2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
16.	Mitral valve insufficiency. Etiology. Pathogenesis of hemodynamic disorders. Clinic. Forecast.	UK-1.1.3, GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3
17.	Infectious endocarditis. Etiopathogenesis. Contributing factors. Classification. Clinic. Treatment. Medical examination.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
18.	Mitral stenosis. Etiology. Pathogenesis of hemodynamic disorders. Stages of the current. Complications. Forecast. Indications for surgical treatment. Opportunities of specialized clinics in the Volgograd region. Medical examination.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
19.	Combined mitral defect. Diagnostics. Modern methods of instrumental diagnostics of heart defects used in cardiological clinics of the Volgograd region. Detection of predominance of stenosis and insufficiency. Clinic.	UK-1.1.3, GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3
20.	Aortic valve insufficiency. Etiology. Pathogenesis of hemodynamic disorders. Clinic of complications. Forecast. Indications for surgical treatment. Opportunities of specialized clinics in the Volgograd region.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
21.	Aortic stenosis. Etiology. Pathogenesis of hemodynamic disorders. Clinic. Diagnosis. Complications. Forecast.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-

	Indications for surgical treatment. Opportunities of specialized clinics in the Volgograd region.	6.2.3, GPC-6.2.4; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
22.	Insufficiency of the 3-leaf valve. Relative and organic insufficiency. Etiology of hemodynamic disorders. Treatment. Indications for surgical treatment. Opportunities of specialized clinics in the Volgograd region.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
23.	Hypertension. Epidemiology. Etiology and pathogenesis.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-4.1.1, GPC-4.1.2, GPC-4.1.3, GPC-4.2.1, GPC-4.2.2, GPC-4.2.3, GPC-4.2.4, GPC-4.3.1, GPC-4.3.2, GPC-4.3.3; GPC-5.1.1, GPC-5.2.1.
24.	Classification of hypertension. Clinic. Course. Hemodynamic variants.	UK-1.1.3, GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3
25.	Arterial hypertension. Definition. Epidemiology. Etiology. Pathophysiology. Clinic. Diagnostics. Modern diagnostic methods used for patients with arterial hypertension in cardiological clinics of the Volgograd region. Classification of hypertension according to the recommendations of the IOC. Risk stratification criteria based on evidence-based medicine.	UK-1.1.3, GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3
26.	Management tactics for patients with arterial hypertension: goals of therapy, general principles, lifestyle changes, drug therapy (choice of antihypertensive drug, effective combinations). Indications for hospitalization.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
27.	Complications of hypertension. Crises, heart failure, nephroangiosclerosis.	UC-1.1.3, UC-1.2.1; GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-1.1.1, PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8, PC-

		1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
28.	Treatment of hypertension. Differential therapy. Evaluation of the effectiveness of hypertension treatment.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
29.	Relief of hypertensive crises. Treatment of heart failure and nephroangiosclerosis.	UC-1.1.3, UC-1.2.1; GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-1.1.1, PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8, PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
30.	Atherosclerosis as a social problem. Epidemiology. Pathogenesis. Features of clinical manifestations depending on the localization. Classification.	UK-1.1.3, GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3
31.	Prevention of atherosclerosis primary and secondary. Therapeutic and preventive use of medicines.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
32.	IHD. Epidemiology. Social significance. Risk factors. Classification.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-4.1.1, GPC-4.1.2, GPC-4.1.3, GPC-4.2.1, GPC-4.2.2, GPC-4.2.3, GPC-4.2.4, GPC-4.3.1, GPC-4.3.2, GPC-

		4.3.3; GPC-5.1.1, GPC-5.2.1.
33.	Angina pectoris. Classification. Pathogenesis of pain syndrome. Clinic.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-4.1.1, GPC-4.1.2, GPC-4.1.3, GPC-4.2.1, GPC-4.2.2, GPC-4.2.3, GPC-4.2.4, GPC-4.3.1, GPC-4.3.2, GPC-4.3.3; GPC-5.1.1, GPC-5.2.1.
34.	Stable angina pectoris of tension. Definition, clinical picture, atypical manifestations and equivalents of tension angina. Modern classification. Modern methods of angina diagnostics used in cardiology clinics of the Volgograd region. Differential diagnostics:	UK-1.1.3, GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3
35.	Diagnostic criteria for coronary heart disease. Significance of instrumental diagnostic methods. Functional tests. Invasive methods of examination. Opportunities of specialized clinics in the Volgograd region.	UK-1.1.3, GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3
36.	Standards for the treatment of coronary heart disease. Relief and prevention of pain attacks. Prevention is primary and secondary. Indications for surgical treatment. Forecast. ITU issues.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
37.	Acute myocardial infarction. Epidemiology. Risk factors. Pathogenesis. Clinic. Course. Periods. Diagnostic criteria. Syndromes of acute myocardial infarction.	UC-1.1.3, UC-1.2.1; GPC-5.1.1, GPC-5.2.1; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15
38.	Complications of acute myocardial infarction: cardiogenic shock, rhythm disturbances, heart failure, aneurysm. Differential diagnosis. Treatment.	UC-1.1.3, UC-1.2.1; GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-1.1.1, PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8, PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
39.	Treatment of acute myocardial infarction.	UC-1.1.3, UC-1.2.1; GPC-5.1.1, GPC-5.2.1;

	Pre-hospital care. Medical tactics in different periods of illness. Thrombolytic therapy: methods, indications and contraindications. The concept of reperfusion syndrome. The role of specialized cardiac ambulances and intensive care units.	GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-1.1.1, PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8, PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
40.	Emergency treatment of rhythm disorders and acute heart failure in myocardial infarction.	UC-1.1.3, UC-1.2.1; GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-1.1.1, PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8, PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
41.	Rehabilitation of patients with acute myocardial infarction. Stages of rehabilitation in Volgograd and the Volgograd region. Ethical and deontological aspects of management of patients with myocardial infarction. Medical examination.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
42.	Chronic heart failure. Definition. Principles of diagnosis: symptoms, instrumental and laboratory diagnostics. Load tests. Classification of the severity of CHF. Algorithm for making a diagnosis based on national recommendations for the diagnosis and treatment of CHF.	UK-1.1.3, GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3
43.	Classification of heart failure. Clinical manifestations. The concept of "hidden" heart failure. Detection of early stages of heart failure. Differential diagnosis.	UK-1.1.3, GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3
44.	Treatment of chronic heart failure.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1,

	Ethical and deontological aspects of management of patients with chronic heart failure. Mode.	GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
45.	Atrial fibrillation and flutter. Pathogenesis. Classification. Clinical symptoms. ECG changes. Effect of atrial fibrillation on hemodynamics. Complications. Treatment of paroxysmal atrial fibrillation. Indications for electropulse therapy. Prevention of recurrent atrial fibrillation. Rules for prescribing new oral anticoagulants, taking into account the risk of thromboembolism on the CHA2DS2-VASc scale and the risk of bleeding on the HAS-BLED scale.	UK-1.1.3, UK-1.2.1; GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-1.1.1, PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8, PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
46.	Extrasystole. Pathogenesis. Clinical manifestations. Classification of extrasystoles. Topical diagnostics. ECG signs. Treatment. Indications for the use of antiarrhythmic drugs.	UC-1.1.3, UC-1.2.1; GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-1.1.1, PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8, PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
47.	Paroxysmal tachycardia. Pathogenesis. Clinical picture of paroxysmal tachycardia attack. ECG changes. Changes in systemic hemodynamics during an attack. Relief of paroxysmal tachycardia.	UC-1.1.3, UC-1.2.1; GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-1.1.1, PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8, PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
48.	Violation of conductivity. Pathogenesis. Classification. Clinical manifestations.	UC-1.1.3, UC-1.2.1; GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-

	The nature of ECG changes. Complications (Morgagni-Edems-Stokes syndrome, heart failure, rhythm disorders). Diagnosis and differential diagnosis. The role of ECG monitoring. Treatment. Indications for temporary electrical stimulation. Indications for pacemaker implantation. Clinics in Volgograd that perform pacemaker implantation operations. Forecast.	7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-1.1.1, PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8, PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
Diseases of the digestive		
49.	system Chronic gastritis. Prevalence. Etiology and pathogenesis. Classification. Clinic. Differential diagnosis. Gastritis associated with HP infection. Treatment.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
50.	Chronic atrophic, autoimmune gastritis. Special forms of chronic gastritis. Differential diagnosis. Treatment.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
51.	Peptic ulcer of the stomach and duodenum 12. Etiology. Pathogenesis. Classification.	UK-1.1.3, GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3
52.	Clinic of gastric ulcer. Features of the clinic depending on the location of the ulcer. Significance of instrumental survey methods. Methods of diagnosis of helicobacter pylori infection:	UK-1.1.3, GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3
53.	Complications of peptic ulcer disease. Special forms of peptic ulcer disease	UC-1.1.3, UC-1.2.1; GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-

	(pyloric, giant, post-bulbar, juvenile, senile).	7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-1.1.1, PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8, PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
54.	Standards of peptic ulcer diagnosis and treatment. Criteria for the effectiveness of treatment. Helicobacter eradication Control pylori.	UK-1.1.3, UK-1.2.1; GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
55.	Inflammatory bowel diseases. Non-specific ulcerative colitis. Crohn's disease. Etiology and pathogenesis. Intestinal and extra-intestinal clinical manifestations. Diagnostics. Complications. Treatment.	UC-1.1.3, UC-1.2.1; GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-1.1.1, PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8, PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
56.	Functional diseases of the gastrointestinal tract. Etiology. Pathogenesis. Clinic. The importance of endoscopy and gastrobiopsy in diagnosis. Treatment.	UC-1.1.3, UC-1.2.1; GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
57.	Stomach cancer. The concept of precancerous diseases of the stomach. Clinical forms. Flow options. Meaning of the "small signs" syndrome. Stages of the	UC-1.1.3, UC-1.2.1; GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-

	disease. Diagnostic criteria. Principles of treatment. Differential diagnosis. Ethical and deontological aspects of cancer management.	2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
Diseases of the liver and biliary tract.		
58.	Chronic hepatitis. Etiology. Pathogenesis. Classification.	UK-1.1.3, GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3
59.	Features of the course of various forms of chronic viral hepatitis. Basic clinical and laboratory syndromes. Verification of the diagnosis. Differential diagnosis. Disease outcomes. Indicators of morbidity and mortality of the working-age population from viral hepatitis in the Volgograd region.	UK-1.1.3, GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3
60.	Principles of treatment of chronic hepatitis. Criteria for the effectiveness of treatment. Prevention. Medical examination.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
61.	Cirrhosis of the liver. Definition. Etiology. Pathogenesis. Classification. Clinical and morphological syndromes. Features of the clinic, course, and diagnosis of viral cirrhosis of the liver. Principles of treatment. Antiviral treatment.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
62.	Clinic and diagnosis of primary biliary cirrhosis of the liver. Differential diagnosis. Treatment.	UK-1.1.3, GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
63.	Autoimmune hepatitis. Clinical features. Types of autoimmune hepatitis:	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1;

	laboratory markers. Differential diagnosis. Treatment.	GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
64.	Clinic and differential diagnosis of alcoholic cirrhosis of the liver. Indicators of morbidity and mortality of the working-age population from alcoholic cirrhosis of the liver in the Volgograd region. Principles of treatment. Ethical and deontological aspects of managing patients with social adaptation disorders.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-1.1.1, PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8, PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
65.	Complications of cirrhosis of the liver: cirrhosis-cancer, hepatic coma, edematous-ascitic syndrome, hypersplenism, bleeding.	UC-1.1.3, UC-1.2.1; GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-1.1.1, PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8, PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
66.	Principles of treatment of cirrhosis of the liver. Diet and medications. Treatment of complications. Prevention. Medical examination.	UC-1.1.3, UC-1.2.1; GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-1.1.1, PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8, PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
67.	Chronic pancreatitis. Etiology. Pathogenesis. Classification. Clinic.	UK-1.1.3, GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; PC-2.1.4, PC-

	Laboratory and instrumental diagnostics.	2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3
68.	Treatment of chronic pancreatitis. Diet. Differentiated drug therapy, taking into account the form and phase of the disease. Indications for surgical treatment. Prevention.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
69.	Chronic cholecystitis. Etiopathogenesis. Clinic. Laboratory and instrumental diagnostics. Treatment.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
Nephrology		
70.	Acute diffuse glomerulonephritis. Etiopathogenesis. Classification. Main clinical syndromes. Criteria for diagnosis. Complications. Principles of treatment of acute nephritis. Outcomes. Forecast.	UC-1.1.3, UC-1.2.1; GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-1.1.1, PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8, PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
71.	Chronic diffuse glomerulonephritis. Modern concepts of etiology and pathogenesis. Clinical classification. Laboratory and instrumental diagnostic methods. Clinic. Complications.	UC-1.1.3, UC-1.2.1; GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-1.1.1, PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8, PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.

72.	Principles of treatment of a patient with chronic diffuse glomerulonephritis. Secondary prevention. Criteria for the effectiveness of treatment. Stages of chronic kidney disease. Using electronic calculators to calculate GFR.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1; GPC-6.1.1, GPC-6.1.2, GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.1.1, GPC-10.1.2, GPC-10.2.1, GPC-10.2.2; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
Hematology		
73.	Modern classification of anemia. Iron deficiency anemia. Etiopathogenesis. The concept of hidden iron deficiency. Clinical picture. The main syndromes. Criteria for diagnosis. Treatment.	UC-1.1.3, UC-1.2.1; GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-1.1.1, PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8, PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
74.	Chronic myeloid leukemia. Etiology and pathogenesis. Main clinical syndromes. Clinical and hematological criteria for diagnosis. Application of standard cytogenetic research, immunotyping. Diagnostic capabilities of clinics in the Volgograd region. Stages of the current. Complications. Outcomes. Principles of treatment. Criteria for hematological remission. Forecast.	UC-1.1.3, UC-1.2.1; GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-1.1.1, PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8, PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
75.	Chronic lymphocytic leukemia. Etiology and pathogenesis. Main clinical syndromes. Diagnostic criteria for CLL. Opportunities for immunotyping in the Volgograd region. Stages of the current. Complications. Principles of treatment. Criteria for hematological remission. Forecast.	UC-1.1.3, UC-1.2.1; GPC-5.1.1, GPC-5.2.1; GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; PC-1.1.1, PC-1.1.2, PC-1.1.3, PC-1.1.4, PC-1.1.5, PC-1.1.6, PC-1.1.7, PC-1.1.8, PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4; PC-2.1.4, PC-2.1.6, PC-2.1.7, PC-2.1.8, PC-2.1.9, PC-2.2.1, PC-2.2.2, PC-2.2.3, PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.

Physical therapy		
76.	Mud therapy. Classification of therapeutic mud. Physiological effect. Indications and contraindications. Therapeutic effect of Lake Elton mud, indications.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1, GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1, PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
77.	Ultrasound. Physical characteristics. Therapeutic effects. Indications and contraindications. Equipment.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1, GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1, PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
78.	Ultraviolet radiation. Mechanism of action. Sources of integral and selective radiation, methods and techniques of general and local irradiation, the concept of the biological dose of ultraviolet radiation. Indications and contraindications. Equipment.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1, GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1, PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
79.	Light. Physical characteristics of the light flux, features of the biological effect of various parts of the spectrum (visible light, monochromatic radiation). Mechanism of action. Indications and contraindications. Equipment.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1, GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1, PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
80.	Amplipulstherapy. Current characteristics. Mechanism of action. Indications and contraindications. Equipment.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1, GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1, PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
81.	Aerosol and eletroaerosol therapy. Properties of medicinal aerosols. Mechanism of action. Types of inhalations. Indications and contraindications. Equipment.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1, GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1, PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
82.	Inductothermy. Mechanism of action. Indications and contraindications. Mobile devices.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1, GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1, PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
83.	Diadynamic currents (Bernard currents). Current characteristics. Mechanism of action. Indications and contraindications. Mobile devices.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1, GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1, PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
84.	Darsonvalization. Mechanism of action. Indications and contraindications. Mobile devices.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1, GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1, PC-

		3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
85.	Ultrahigh frequency (UHF) electric field. Mechanism of action. Indications and contraindications. Mobile devices.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1, GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1, PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
86.	Microwave therapy in the methods of centimeter (CM) and decimeter (DMV) ranges. Mechanism of action. Indications and contraindications. Equipment.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1, GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1, PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
87.	Drug electrophoresis. Therapeutic effects. Methods of electrophoresis. Indications and contraindications. Mobile devices.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1, GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1, PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
88.	The concept of the resort. Types of climate therapy. The main climatic resorts. General contraindications for going to resorts. Features of sanatorium treatment in health resorts of the Volgograd region.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1, GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1, PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
89.	Classification of medicinal mineral waters. Mechanism of action and method of application of mineral waters in cholecystitis and peptic ulcer disease.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1, GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1, PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
90.	Balneological resorts. Classification. The main indications for referral to balneological resorts.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1, GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1, PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
91.	Ozone therapy. Mechanism of action. Indications and contraindications.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1, GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1, PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.
92.	Magnetic therapy. Mechanism of action. Indications and contraindications. Mobile devices.	UC-1.1.3, UC-1.2.1; GPC-1.1.1, GPC-1.2.1, GPC-1.2.2; GPC-5.1.1, GPC-5.2.1, GPC-7.1.1, GPC-7.1.2, GPC-7.1.3, GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1, PC-3.1.1, PC-3.1.2, PC-3.1.3, PC-3.1.4, PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.

2.2. Example of a situational problem

Verifiable indicators of competence achievement: CC-1.2.1; GPC-1.2.1, GPC-1.2.2; GPC-4.2.1, GPC-4.2.2, GPC-4.2.3, GPC-4.2.4, GPC-4.3.1, GPC-4.3.2, GPC-4.3.3; GPC-5.2.1; GPC-6.2.1, GPC-6.2.3, GPC-6.2.4; GPC-7.2.1, GPC-7.2.2, GPC-7.2.3, GPC-7.3.1; GPC-10.2.1, GPC-10.2.2; PC-1.2.1, PC-1.2.2, PC-1.2.3, PC-1.2.4, PC-2.2.1, PC-2.2.2, PC-2.2.3,

PC-2.2.4, PC-2.2.5, PC-2.2.6, PC-2.2.7, PC-2.2.8, PC-2.2.9, PC-2.2.10, PC-2.2.12, PC-2.2.14, PC-2.2.15, PC-2.3.1, PC-2.3.2, PC-2.3.3; PC-3.2.1, PC-3.2.2, PC-3.2.4, PC-3.3.1.

Patient K., 45 years old, was taken to the clinic in serious condition. I got sick the night before, right after dinner, which was eaten by the whole family. There were severe pains in the epigastric region, vomiting first with food eaten, and then with gastric contents. The pain lasted 3 hours. The emergency doctor called washed the stomach, suspecting food poisoning. There was no improvement, and the patient was taken to the hospital.

During the last year, the patient has noticed the occurrence of pain behind the sternum during brisk walking and physical exertion, which forced him to stop, rest and soon passed. These pains occurred 1-2 times a month.

Objectively: the patient's condition is severe, cyanosis of the face, cold, covered with sticky sweat body. Pulse 110 per minute, small, fast. The temperature is 36.9° C. Blood pressure is 80/50 mm Hg. The borders of the heart are not changed, the tones are deaf. In the lungs, vesicular respiration, no wheezing, BH 22 per minute. The tongue is covered with a gray coating. The abdomen is of normal shape, not swollen, soft on palpation, moderately painful in the epigastric region. There are no symptoms of peritoneal irritation. An. of blood: hemoglobin 140 g/l, er. $4,2 \times 10^{12}$, leukocytes $11,2 \times 10^9$, p 4, c 70, l 23, m 3, ESR 10 mm/h, CPK MV 84 U/l. There is no urine in the bladder. ECG: sinus tachycardia, reduced voltage of the R wave in the II, W, AVFAVF leads, ST is domed up in the II, III, AVFAVF leads, ST in the I, VV4, VV5, V6 leads below the contour line.

Questions:

- 1) Your preliminary diagnosis?
- 2) What mistake did the ambulance doctor make?
- 3) What are the emergency measures needed to bring the patient out of this state?

2.3. Example of radiographs, ECGs, and laboratory tests.

Verifiable indicators of competence achievement: GPC-4.2.4, GPC-5.2.1, PC-2.2.6.

- 1) X-ray of the stomach with contrast: peptic ulcer.
- 2) ECG: atrial fibrillation.
- 3) laboratory tests: B12 deficiency anemia.

2.4. Sample exam card

Federal State Budgetary Educational Institution of Higher Education "Volgograd State Medical University"
of the Ministry of Health of the Russian Federation

Department: Faculty therapy

Discipline: Faculty therapy

Specialty 31.05.01 Medical science, orientation (profile) Medical business

Academic year: 2023-2024

The question card № 1

(interview)

Exam questions:

1. Tricuspid valve insufficiency. Etiology. Pathogenesis. Hemodynamic disorders.

Clinic. Diagnostics.

2. Acute glomerulonephritis. Etiology. Pathogenesis. Diagnostics. Treatment. Complications of acute diffuse glomerulonephritis and their treatment.
3. Laser therapy. Mechanism of action. Methodology. Indications and contraindications. Mobile devices.

P.S. Head of the Department _____ A. R. Babaeva

The full fund of assessment funds for the discipline is available in the EIE of VolgSMU at the link (s):

<https://elearning.volgmed.ru/>.....

Considered at the meeting of the Department of Faculty therapy " 24 " May 2023, Protocol No. 10.

Head of the Department
Faculty of Therapy, MD, Professor



A. R. Babaeva

Signature